Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age: ≥ 18 years old, ≤ 75 years old.

• Pathological histologic confirmation of cervical cancer.

• Imaging or PET/CT examination can be performed to understand the tumor and complete all follow-up.

• Measurable lesions before treatment.

• Good physical condition: ECOG score 0-1 (or KPS score 70-100).

• Estimated survival≥ 6 months.

• The baseline blood routine and biochemical indexes before radiotherapy and chemotherapy met the following standards: hemoglobin ≥ 80g/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT, AST ≤ 2.5 times the normal upper limit; Serum albumin ≥ 30 g/L.

• There are three preoperative items: if the patient has syphilis, plum repellent therapy is required before treatment.

• The patient has no history of allergy to rubber products.

• Cardiopulmonary function is basically normal

Locations
Other Locations
China
Yong Li
RECRUITING
Guiyang
Contact Information
Primary
Yong Li, Chief physician
liyong7229771@163.com
13628566285
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 30
Sponsors
Leads: Guizhou Provincial People's Hospital

This content was sourced from clinicaltrials.gov